IP Library Granted Patent US 11,154,618
Granted Patent B2
US 11,154,618 · App. 15/216,344 · Granted Oct 26, 2021

Systems and methods for treatments of an eye with a photosensitizer

Inventors: Pavel Kamaev (Lexington, MA); Marc D. Friedman (Needham, MA)
Assignee: Avedro, Inc.
A61K41/0057A61F9/0017A61F9/0079A61K9/0048A61K31/525A61K33/00A61K33/26A61N5/062A61P27/02A61P43/00A61N2005/0661
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,154,618
App. No.
15/216,344
Granted
Oct 26, 2021
Kind
B2
Abstract

A formulation for an eye treatment includes a photosensitizer and a permeability enhancing composition. The permeability enhancing composition includes one or more permeability enhancers. The permeability enhancing composition has a hydrophilic and lipophilic balance increases a permeability of an area of the eye for the photosensitizer. The hydrophilic and lipophilic balance can be characterized by a Hydrophile-Lipophile Balance (HLB) number. For example, the area of the eye may include a corneal epithelium, the photosensitizer may include riboflavin, and the permeability enhancing composition may have a corresponding HLB number between approximately 12.6 and approximately 14.6.

Claims (16)

1. A formulation for an eye treatment, comprising:

a photosensitizer solution including a photosensitizer that, in response to absorbing photoactivating illumination, produces reactive radicals that interact with corneal tissue to generate cross-linking activity in the corneal tissue, the photosensitizer having molecules that are large relative to tight junctions of an epithelium of the corneal tissue; and

a permeability enhancing composition including at least one of IGEPAL CO-630, Triton X-100, Polidocanol, or IGEPAL CO-720,

wherein the photosensitizer solution includes a concentration of at least 0.1% riboflavin.

2. The formulation of claim 1 , further comprising at least one additive selected from the group consisting of iron, copper, manganese, chromium, vanadium, aluminum, cobalt, mercury, cadmium, nickel, arsenic, 2,3-butanedione, and folic acid.

3. The formulation of claim 1 , further comprising at least one additive including iron.

4. A method for treating an eye, comprising:

applying a formulation to corneal tissue, the formulation including:

a photosensitizer solution including a photosensitizer that, in response to absorbing photoactivating illumination, produces reactive radicals that interact with the corneal tissue to generate cross-linking activity in the corneal tissue, the photosensitizer having molecules that are large relative to tight junctions of an epithelium of the corneal tissue; and

a permeability enhancing composition including at least one of IGEPAL CO-630, Triton X-100, Polidocanol, or IGEPAL CO-720; and

photoactivating the photosensitizer by delivering a dose of illumination to the corneal tissue,

wherein the photosensitizer solution includes a concentration of at least 0.1% riboflavin.

5. The method of claim 4 , wherein the formulation further includes at least one additive selected from the group consisting of iron, copper, manganese, chromium, vanadium, aluminum, cobalt, mercury, cadmium, nickel, arsenic, 2,3-butanedione, and folic acid.

6. The method of claim 4 , further comprising at least one additive including iron.

7. The formulation of claim 1 , wherein the photoactivating illumination is ultraviolet light, and in response to absorbing the ultraviolet light, the photosensitizer undergoes a reaction with oxygen to produce at least reactive oxygen species that interact with corneal collagen fibrils to induce covalent bonds that bind together amino acids of the collagen fibrils, thereby crosslinking the fibrils.

8. The method of claim 4 , wherein the photoactivating illumination is ultraviolet light, and in response to absorbing the ultraviolet light, the photosensitizer undergoes a reaction with oxygen to produce at least reactive oxygen species that interact with corneal collagen fibrils to induce covalent bonds that bind together amino acids of the collagen fibrils, thereby crosslinking the fibrils.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 21, 2019
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: AVEDRO, INC.
Reel/Frame 051080/0756 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NO. 14/140,184 PREVIOUSLY RECORDED AT REEL: 042167 FRAME: 0671. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 1, 2017
From: AVEDRO, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042390/0659 →
SECURITY INTEREST Recorded Apr 27, 2017
From: AVEDRO, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042167/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2016
From: FRIEDMAN, MARC D.
To: AVEDRO, INC.
Reel/Frame 039917/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2016
From: KAMAEV, PAVEL
To: AVEDRO, INC.
Reel/Frame 039915/0074 →
Continuity (5)
Provisional Application 62263598 · Dec 4, 2015
Provisional Application 62262919 · Dec 4, 2015
Provisional Application 62255452 · Nov 14, 2015
Provisional Application 62195144 · Jul 21, 2015
Related Publication 20170021021A1 · Jan 26, 2017